You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

How the Care Team Concept Applies to the Management of Cutaneous Fungal Diseases

  • Authors: David M. Pariser, MD; Dyanne P. Westerberg, DO; Wendy Cantrell, DNP, CRNP
  • CME / CE Released: 1/14/2016
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/14/2017
Start Activity


Target Audience and Goal Statement

This activity is intended for dermatologists, primary care physicians, podiatrists, advanced practice providers, and nurses who treat patients with onychomycosis.

The goal of this activity is to illustrate individual and collaborative roles of different clinicians in the care of patients with onychomycosis.

Upon completion of this activity, participants will be able to:

  1. Identify collaborative and individual roles of the healthcare team in the management of onychomycosis
  2. Determine best practices in communication strategies to educate patients with onychomycosis
  3. Describe appropriate therapeutic strategies to optimize patient outcomes in the management of onychomycosis


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator(s)

  • David M. Pariser, MD

    Professor, Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia

    Disclosures

    Disclosure: David M. Pariser, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bickel Biotechnology; Biofrontera AG; Celgene Corporation; Demira; DUSA Pharmaceuticals, Inc.; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Valeant Pharmaceuticals International
    Received grants for clinical research from: Abbott Laboratories; Amgen, Inc.; Bickel Biotechnology; Celgene Corporation; LEO Pharma, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Novo Nordisk; Ortho Dermatologics; Peplin Inc.; Pfizer Inc; Photocure ASA; Stiefel Laboratories, Inc.; Valeant Pharmaceuticals International

    Dr Pariser does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Pariser does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

  • Wendy Cantrell, DNP, CRNP

    Assistant Professor, University of Alabama at Birmingham, Department of Dermatology, Birmingham, Alabama

    Disclosures

    Disclosure: Wendy Cantrell, DNP, CRNP, has disclosed no relevant financial relationships.

    Dr Cantrell does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Cantrell does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Dyanne P. Westerberg, DO

    Associate Professor, Cooper Medical School of Rowan University, Camden, New Jersery

    Disclosures

    Disclosure: Dyanne P. Westerberg, DO, has disclosed no relevant financial relationships.

    Dr Westerberg does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Westerberg does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

  • Boni E. Elewski, MD

    Professor, University of Alabama, Birmingham

    Disclosures

    Disclosure: Boni E. Elewski, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Anacor Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Valeant Pharmaceuticals International
    Received grants for clinical research from: AbbVie Inc; Amgen, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Valeant Pharmaceuticals International

  • Aditya K. Gupta, MD, PhD, FRCPC, FAAD, MBA

    Professor, University of Toronto, Toronto, Ontario

    Disclosures

    Disclosure: Aditya K. Gupta, MD, PhD, FRCPC, FAAD, MBA, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Anacor Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Moberg Pharma; Valeant Pharmaceuticals International
    Received grants for clinical research from: Valeant Pharmaceuticals International Clinical trials investigator: Lilly; Merck & Co., Inc.; UCB Pharma, Inc.

  • Jeffrey M. Robbins, DPM

    Professor of Podiatric Medicine; Director, Podiatry Services VACO; Kent State University College of Podiatric Medicine, Independence, Ohio

    Disclosures

    Disclosure: Jeffrey M. Robbins, DPM, has disclosed no relevant financial relationships.

  • Antonella Tosti, MD

    Professor, Department of Dermatology & Cutaneous Surgery, University of Miami, Miami, Florida

    Disclosures

    Disclosure: Antonella Tosti, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Anacor Pharmaceuticals, Inc.; PharmaDerm; Polichem; Valeant Pharmaceuticals International; Viamet Pharmaceuticals Holdings, LLC
    Served as a speaker or a member of a speakers bureau for: PharmDerm; Sandoz

  • Tracey C. Vlahovic, DPM, FFPM RCPS (Glasg)

    Associate Professor, Temple University School of Podiatric Medicine, Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Tracey C. Vlahovic, DPM, FFPM RCPS (Glasg), has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Pharmaderm; Valeant Pharmaceuticals International

  • Dyanne P. Westerberg, DO

    Associate Professor, Cooper Medical School of Rowan University, Camden, New Jersey

    Disclosures

    Disclosure: Dyanne P. Westerberg, DO, has disclosed no relevant financial relationships.

Editor(s)

  • Shari J. Dermer, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Shari J. Dermer, PhD has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

How the Care Team Concept Applies to the Management of Cutaneous Fungal Diseases

Authors: David M. Pariser, MD; Dyanne P. Westerberg, DO; Wendy Cantrell, DNP, CRNPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / CE Released: 1/14/2016

Valid for credit through: 1/14/2017

processing....

Editor's Note: An interprofessional approach to treatment of patients with onychomycosis may be particularly valuable because of patient comorbidities and recurrent infection. Good communication between the different members of the team that includes the primary care physician, dermatologist, and nurse practitioner is essential. The activity presented here illustrates how the interprofessional approach can work in this setting.

This feature requires the newest version of Flash. You can download it here.
  • Print